 EDISON, N.J., April 29, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, Hepion, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI - driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, announced that its Senior Vice-President, Clinical Pharmacology and Analytics, Dr. Patrick Mayo, gave a virtual presentation entitled CRV431 From Benchtop to Bedside Clinical Development today at the 4th Global NASH Congress. 